每年的ASCO是搞肿瘤科的最大的一个年会。近些年美国在这方面的领先被欧洲和亚洲的医学系统挑战，所以ESMO也非常值得去。这样级别的大会，信息如同风暴，令人措手不及。会场也是迷宫一般。所以下周开会之前，我先把摘要浏览总结一下。在社区工作需要对多种疾病的进展都有所了解。
Plenary session （全体会议): :这是会议的亮点，不能错过。
1. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
By Paul Richardson
From JCO 2022: https://ascopubs.org/doi/10.1200/JCO.19.02515
RVD is an induction regimen that delivers high response rates (VGPR or better) in close to 90% of patients after transplantation, and risk-adapted maintenance can deliver unprecedented long-term outcomes. This study includes the largest cohort of patients treated with RVD reported to date with long follow-up and demonstrates the ability of 3-drug induction regimens in patients with newly diagnosed multiple myeloma to result in a substantial survival benefit.
2. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
By Yoshino from Japan. 这事在美国已经翻篇了，没有很多争议，和left colon vs. right-sided colon有关。看看日本的数据有什么新发现。
3. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
这绝对是重磅，我赌这个数据非常好, could be practice changing
4. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
很少看肉瘤，飘过
Ref:
http://t.email.asco.org/r/?id=ha36fb31,718c205,36aa5da&cid=DM10518&bid=171375409&p1=%4098bdmaDhGD2AQ3W5%2FzkZ2zROg9T3TGCLNgbFYo4eFSo%3D
